Frank Mongillo, MD
Internal Medicine · New Haven, CTNPI 1811917289
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 64.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $6,766 and has fallen 98.9% since, to $75 in 2025. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $76.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$8K
- GSK$783
- Novo Nordisk$671
- Amgen$418
- Bayer$345
- AbbVie$299
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$6,45051%
- Travel & lodging$1,0378%
- Food & beverage$4,99340%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 36 | $8,117 |
| GSK | 9 | $783 |
| Novo Nordisk | 24 | $671 |
| Amgen(2 entities) | 7 | $418 |
| Bayer | 15 | $345 |
| AbbVie(2 entities) | 18 | $299 |
| AstraZeneca | 4 | $282 |
| Lilly USA, LLC | 4 | $238 |
| Novartis | 4 | $223 |
| Eisai Inc. | 15 | $193 |
| Braeburn Inc. | 4 | $163 |
| E.r. Squibb & Sons, L.L.C. | 7 | $127 |
| Merck | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $120 |
| Astellas Pharma US Inc | 1 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Redhill Biopharma Inc. | 1 | $48 |
| Orexo US, Inc. | 3 | $45 |
| Pfizer | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| TMS Neurohealth Centers Inc. | 1 | $28 |
| Bardy Diagnostics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,580 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $106,631 |
| JanuviaSitagliptin Phosphate | 34 | $43,054 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $34,359 |
| FarxigaDapagliflozin Propanediol | 32 | $34,075 |
| MounjaroTirzepatide | 23 | $28,652 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 131 | $21,103 |
| RexultiBrexpiprazole | 11 | $15,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,079 |
| EliquisApixaban | 12 | $13,738 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $9,562 |
| Midodrine Hcl | 17 | $2,446 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 99 | $2,279 |
| FenofibrateFenofibrate Nanocrystallized | 44 | $2,278 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $2,125 |
| Atorvastatin Calcium | 323 | $2,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $671 | $106,631105 claims |
| MerckJanuvia | $125 | $43,05434 claims |
| Indivior Inc.Suboxone | $8,117 | $34,35942 claims |
| AstraZenecaFarxiga | $282 | $34,07532 claims |
| Lilly USA, LLCMounjaro | $238 | $28,65223 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $30 | $15,90711 claims |
| GSKTrelegy Ellipta | $783 | $15,07924 claims |
| PfizerEliquis | $39 | $13,73812 claims |
| AbbVieSynthroid | $299 | $1,54211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in New Haven
- Nancy BrownNew Haven$1.6M
- Richard LiftonNew Haven$160K
- Wayne WarrenNew Haven$127K
- Marcella SmithNew Haven$66K
- Sanjay AggarwalNew Haven$54K
- Bubu BaniniNew Haven$39K
- Sandra SpringerNew Haven$39K
- Karen WangNew Haven$38K
- Michael SchilskyNew Haven$36K
- Kenechukwu MezueNew Haven$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.